CD19 and neoplasm: CLL patients treated with BTKi showed a significant reduction in the frequency of circulating CD19+ B cells, consistent with the clinical responses observed following long-term ibrutinib or zanubrutinib treatment (Fig. 1A), however most patients still had detectable tumour cells.